Literature DB >> 18753208

Functional mapping of the human papillomavirus type 16 E1 cistron.

Michael J Lace1, James R Anson, Lubomir P Turek, Thomas H Haugen.   

Abstract

Replication of the double-stranded, circular human papillomavirus (HPV) genomes requires the viral DNA replicase E1. Here, we report an initial characterization of the E1 cistron of HPV type 16 (HPV-16), the most common oncogenic mucosal HPV type found in cervical and some head and neck cancers. The first step in HPV DNA replication is an initial burst of plasmid viral DNA amplification. Complementation assays between HPV-16 genomes carrying mutations in the early genes confirmed that the expression of E1 was necessary for initial HPV-16 plasmid synthesis. The major early HPV-16 promoter, P97, was dispensable for E1 production in the initial amplification because cis mutations inactivating P97 did not affect the trans complementation of E1- mutants. In contrast, E1 expression was abolished by cis mutations in the splice donor site at nucleotide (nt) 226, the splice acceptor site at nt 409, or a TATAA box at nt 7890. The mapping of 5' mRNA ends using rapid amplification of cDNA ends defined a promoter with a transcription start site at HPV-16 nt 14, P14. P14-initiated mRNA levels were low and required intact TATAA (7890). E1 expression required the HPV-16 keratinocyte-dependent enhancer, since cis mutations in its AP-2 and TEF-1 motifs abolished the ability of the mutant genomes to complement E1- genomes, and it was further modulated by origin-proximal and -distal binding sites for the viral E2 gene products. We conclude that P14-initiated E1 expression is critical for and limiting in the initial amplification of the HPV-16 genome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753208      PMCID: PMC2573179          DOI: 10.1128/JVI.00921-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line.

Authors:  J Doorbar; A Parton; K Hartley; L Banks; T Crook; M Stanley; L Crawford
Journal:  Virology       Date:  1990-09       Impact factor: 3.616

2.  The DNA-binding domain of human papillomavirus type 18 E1. Crystal structure, dimerization, and DNA binding.

Authors:  Anitra S Auster; Leemor Joshua-Tor
Journal:  J Biol Chem       Date:  2003-10-30       Impact factor: 5.157

3.  A functional interferon regulatory factor-1 (IRF-1)-binding site in the upstream regulatory region (URR) of human papillomavirus type 16.

Authors:  Istvan Arany; Kenneth J Grattendick; William E Whitehead; Istvan A Ember; Stephen K Tyring
Journal:  Virology       Date:  2003-06-05       Impact factor: 3.616

4.  Identification and characterization of a cluster of transcription start sites located in the E6 ORF of human papillomavirus type 16.

Authors:  Maiken W Rosenstierne; Jeppe Vinther; Christina N Hansen; Martin Prydsoe; Bodil Norrild
Journal:  J Gen Virol       Date:  2003-11       Impact factor: 3.891

5.  Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas.

Authors:  J G Rheinwald; M A Beckett
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

6.  A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions.

Authors:  M Dürst; L Gissmann; H Ikenberg; H zur Hausen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

7.  Splicing of a cap-proximal human Papillomavirus 16 E6E7 intron promotes E7 expression, but can be restrained by distance of the intron from its RNA 5' cap.

Authors:  Zhi-Ming Zheng; Mingfang Tao; Koji Yamanegi; Sohrab Bodaghi; Wei Xiao
Journal:  J Mol Biol       Date:  2004-04-09       Impact factor: 5.469

8.  The upstream regulatory region of the human papilloma virus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones.

Authors:  B Gloss; H U Bernard; K Seedorf; G Klock
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

9.  Transcriptional regulation of the human papillomavirus-16 E6-E7 promoter by a keratinocyte-dependent enhancer, and by viral E2 trans-activator and repressor gene products: implications for cervical carcinogenesis.

Authors:  T P Cripe; T H Haugen; J P Turk; F Tabatabai; P G Schmid; M Dürst; L Gissmann; A Roman; L P Turek
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

10.  Transient replication of BPV-1 requires two viral polypeptides encoded by the E1 and E2 open reading frames.

Authors:  M Ustav; A Stenlund
Journal:  EMBO J       Date:  1991-02       Impact factor: 11.598

View more
  14 in total

1.  Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers.

Authors:  Michael J Lace; James R Anson; Jens P Klussmann; Dong Hong Wang; Elaine M Smith; Thomas H Haugen; Lubomir P Turek
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

2.  Construction of a full transcription map of human papillomavirus type 18 during productive viral infection.

Authors:  Xiaohong Wang; Craig Meyers; Hsu-Kun Wang; Louise T Chow; Zhi-Ming Zheng
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

3.  Characterization of novel transcripts of human papillomavirus type 16 using cap analysis gene expression technology.

Authors:  Ayumi Taguchi; Kazunori Nagasaka; Kei Kawana; Kosuke Hashimoto; Rika Kusumoto-Matsuo; Charles Plessy; Miranda Thomas; Hiroe Nakamura; Alessandro Bonetti; Katsutoshi Oda; Iwao Kukimoto; Piero Carninci; Lawrence Banks; Yutaka Osuga; Tomoyuki Fujii
Journal:  J Virol       Date:  2014-12-10       Impact factor: 5.103

4.  Development of a cellular assay system to study the genome replication of high- and low-risk mucosal and cutaneous human papillomaviruses.

Authors:  Jelizaveta Geimanen; Helen Isok-Paas; Regina Pipitch; Kristiina Salk; Triin Laos; Marit Orav; Tormi Reinson; Mart Ustav; Mart Ustav; Ene Ustav
Journal:  J Virol       Date:  2011-01-19       Impact factor: 5.103

5.  Site-directed mutagenesis of human papillomavirus 18 promoter elements and tissue-specific expression in cervical carcinoma cells.

Authors:  Mandy S Y Lung; Ning Zhang; Vincent Murray
Journal:  Virus Genes       Date:  2012-02-21       Impact factor: 2.332

6.  Upstream regulatory region alterations found in human papillomavirus type 16 (HPV-16) isolates from cervical carcinomas increase transcription, ori function, and HPV immortalization capacity in culture.

Authors:  Michael J Lace; Christina Isacson; James R Anson; Attila T Lörincz; Sharon P Wilczynski; Thomas H Haugen; Lubomír P Turek
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

7.  The E8--E2 gene product of human papillomavirus type 16 represses early transcription and replication but is dispensable for viral plasmid persistence in keratinocytes.

Authors:  Michael J Lace; James R Anson; Gregory S Thomas; Lubomir P Turek; Thomas H Haugen
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

8.  Human papillomavirus (HPV) type 18 induces extended growth in primary human cervical, tonsillar, or foreskin keratinocytes more effectively than other high-risk mucosal HPVs.

Authors:  Michael J Lace; James R Anson; Aloysius J Klingelhutz; John H Lee; Aaron D Bossler; Thomas H Haugen; Lubomir P Turek
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

9.  Productive Lifecycle of Human Papillomaviruses that Depends Upon Squamous Epithelial Differentiation.

Authors:  Naoko Kajitani; Ayano Satsuka; Akifumi Kawate; Hiroyuki Sakai
Journal:  Front Microbiol       Date:  2012-04-24       Impact factor: 5.640

10.  Persistence of an Oncogenic Papillomavirus Genome Requires cis Elements from the Viral Transcriptional Enhancer.

Authors:  Koenraad Van Doorslaer; Dan Chen; Sandra Chapman; Jameela Khan; Alison A McBride
Journal:  MBio       Date:  2017-11-21       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.